Horiike, A., Wakui, H., Sugawara, S., Minegishi, Y., Tasaka, S., Sakatani, T., Suzuki, H., Hosomi, Y., Tambo, Y., Shimokawa, T., Ishida, H., Miyauchi, E., Naoki, K., Fukuhara, T., Takenoshita, S., Inoue, E., Wada, S., Yoshimura, K., Kobayashi, S., Tsunoda, T. (2026). Durable efficacy of first-line necitumumab plus pembrolizumab in PD-L1–high advanced NSCLC: Final results of the phase II K-TAIL-202 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8573